Cargando…
A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example
BACKGROUND: Data on absolute risks of outcomes and patterns of drug use in cost-effectiveness analyses are often based on randomised clinical trials (RCTs). The objective of this study was to evaluate the external validity of published cost-effectiveness studies by comparing the data used in these s...
Autores principales: | van Staa, Tjeerd-Pieter, Leufkens, Hubert G., Zhang, Bill, Smeeth, Liam |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779340/ https://www.ncbi.nlm.nih.gov/pubmed/19997499 http://dx.doi.org/10.1371/journal.pmed.1000194 |
Ejemplares similares
-
Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data
por: Gallagher, Arlene M., et al.
Publicado: (2011) -
Correction: Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data
por: Gallagher, Arlene M., et al.
Publicado: (2013) -
Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database
por: Bhaskaran, Krishnan, et al.
Publicado: (2012) -
Cancer recording in patients with and without type 2 diabetes in the Clinical Practice Research Datalink primary care data and linked hospital admission data: a cohort study
por: Williams, Rachael, et al.
Publicado: (2018) -
Prediction of Cardiovascular Risk Using Framingham, ASSIGN and QRISK2: How Well Do They Predict Individual Rather than Population Risk?
por: van Staa, Tjeerd-Pieter, et al.
Publicado: (2014)